Science
Technology and Economic Assessment Panel reports expected to be produced until 2030 in response to parties’ requests
| Id | Year | Reporting type | Decision | Issue | Request by parties to TEAP | Report to be produced |
|---|---|---|---|---|---|---|
| 0 | 2025 | Progress updates | IV/13 | Technical progress update by TEAP and its TOCs | Decision IV/13 – Report annually to OEWG on technical progress in reducing the use and emissions of controlled substances and assess the use of alternatives, particularly their direct and indirect global-warming effects | 2025 progress report |
| 1 | 2025 | Progress updates | XI/17 | Technical progress update by TEAP and its TOCs | Decision XI/17 – Report on any important new developments on an annual basis | 2025 progress report |
| 2 | 2025 | Progress updates | XXXI/8 | Procedures relevant to nominations to the TEAP and its TOCs. | Decision XXXI/8 – Provide, as part of its annual progress report, a summary outlining the procedures that the Panel and its technical options committees have undertaken to ensure adherence to the Panel’s terms of reference through clear and transparent procedures, including full consultations with the focal points, in line with the terms of reference, regarding: (a) nomination processes, taking into account the matrix of needed expertise and already available expertise; (b) proposed nominations and appointment decisions; (c) termination of appointments; and (d) replacements | 2025 progress report |
| 3 | 2025 | Thematic reports | IX/6 | Critical-use nominations | Decision IX/6 – Review nominations for critical-use exemption of methyl bromide and make recommendations based on the criteria established in the decision (and other relevant decisions) | 2025 progress report (only upon submission of nominations) |
| 4 | 2025 | Thematic reports | IV/25 | Essential-use nominations | Decision IV/25 – Review any submitted nominations and make recommendations in accordance with the criteria established in the decision | 2025 progress report (only upon submission of nominations) |
| 5 | 2025 | Thematic reports | XXXI/5 | Laboratory and analytical uses | Decision XXXI/5 – Report in the TEAP quadrennial report on any progress made by parties in reducing their production and consumption of ozone depleting substances for laboratory and analytical uses, on any new alternatives to those uses, and on laboratory standards that can be performed without such substances, on the understanding that, should new compelling information become available, including opportunities for significant reductions in production and consumption, that information should be reported in its annual progress report | 2025 progress report (only if new compelling information becomes available) |
| 6 | 2025 | Thematic reports | XXXI/6 | Process agents | Decision XXXI/6 – Report in the TEAP quadrennial reports on any progress made by parties in reducing their use and emissions of controlled substances as process agents and on any new alternatives to such uses, including new production processes and emissions-reduction techniques, on the understanding that should new compelling information become available, that information should be reported in its annual progress report | 2025 progress report (only if new compelling information becomes available) |
| 7 | 2025 | Thematic reports | XXX/15 | Process agents; destruction technologies; laboratory and analytical uses; n-propyl bromide; possible new substances | Review only if the specific conditions set out in decision XXX/15 are met | |
| 8 | 2025 | Thematic reports | XXXV/20 | Options for the organization of the technology and economic assessment panel and its technical options committees | Decision XXXV/20 – Provide in its progress report, prepared ahead of the OEWG47 meeting, options on the organization of the Panel and its technical options committees, considering the Panel’s terms of reference established in decision XXIV/8, and informed by consultation with the technical options committees’ co-chairs and members, and by their experiences with operating, on a trial basis, with new ways of organizing their work. | 2025 progress report |
| 9 | 2025 | Thematic reports | XXXVI/2 | Life-cycle refrigerant management | Decision XXXVI/2, paragraph 1– Include updated relevant information on life-cycle refrigerant management in its 2025 and subsequent progress reports, including the 2026 quadrennial assessment report, taking into account discussions at MOP36 | 2025 progress report |
| 10 | 2025 | Thematic reports | XXXVI/3 | Emissions of HFC-23 | Decision XXXVI/3, Paragraph 5 – TEAP and SAP to update decision XXXV/7 reports on HFC-23 to reflect any additional or new information that becomes available, and to submit their reports on the matter to MOP37. Paragraph 6 - TEAP to provide information on and a comparison of best practices and guidelines relating to measuring, estimating, reporting and verifying HFC-23 by-product emissions and their destruction. | Report on HFC-23 emissions |
| 11 | 2025 | Thematic reports | XXXVI/6 | Developments regarding metered-dose inhalers with low-global-warming-potential propellants | Decision XXXVI/6, paragraph 3 – Provide updated information, in its annual progress report, on low-GWP metered-dose inhaler propellants, and to complement its 2026 quadrennial assessment report with timely information including on their availability, technical feasibility, economic viability, safety and market penetration in parties operating under paragraph 1 of Article 5 of the Montreal Protocol and those not so doing | 2025 progress report |
| 12 | 2026 | Progress updates | IV/13 | Technical progress update by TEAP and its TOCs | Decision IV/13 – Report annually to OEWG on technical progress in reducing the use and emissions of controlled substances and assess the use of alternatives, particularly their direct and indirect global-warming effects | 2026 progress report |
| 13 | 2026 | Progress updates | XI/17 | Technical progress update by TEAP and its TOCs | Decision XI/17 – Report on any important new developments on an annual basis | 2026 progress report |
| 14 | 2026 | Progress updates | XXXI/8 | Procedures relevant to nominations to the TEAP and its TOCs. | Decision XXXI/8 – Provide, as part of its annual progress report, a summary outlining the procedures that the Panel and its technical options committees have undertaken to ensure adherence to the Panel’s terms of reference through clear and transparent procedures, including full consultations with the focal points, in line with the terms of reference, regarding: (a) nomination processes, taking into account the matrix of needed expertise and already available expertise; (b) proposed nominations and appointment decisions; (c) termination of appointments; and (d) replacements | 2026 progress report |
| 15 | 2026 | Thematic reports | IX/6 | Critical-use nominations | Decision IX/6 – Review nominations for critical-use exemption of methyl bromide and make recommendations based on the criteria established in the decision (and other relevant decisions) | 2026 progress report (only upon submission of nominations) |
| 16 | 2026 | Thematic reports | IV/25 | Essential-use nominations | Decision IV/25 – Review any submitted nominations and make recommendations in accordance with the criteria established in the decision | 2026 progress report (only upon submission of nominations) |
| 17 | 2026 | Thematic reports | XXXI/5 | Laboratory and analytical uses | Decision XXXI/5 – Report in the TEAP quadrennial report on any progress made by parties in reducing their production and consumption of ozone depleting substances for laboratory and analytical uses, on any new alternatives to those uses, and on laboratory standards that can be performed without such substances, on the understanding that, should new compelling information become available, including opportunities for significant reductions in production and consumption, that information should be reported in its annual progress report | 2026 quadrennial assessment report |
| 18 | 2026 | Thematic reports | XXXI/6 | Process agents | Decision XXXI/6 – Report in the TEAP quadrennial reports on any progress made by parties in reducing their use and emissions of controlled substances as process agents and on any new alternatives to such uses, including new production processes and emissions-reduction techniques, on the understanding that should new compelling information become available, that information should be reported in its annual progress report | 2026 quadrennial assessment report |
| 19 | 2026 | Thematic reports | XXX/15 | Process agents; destruction technologies; laboratory and analytical uses; n-propyl bromide; possible new substances | Review only if the specific conditions set out in decision XXX/15 are met | |
| 20 | 2026 | Thematic reports | XXXVI/2 | Life-cycle refrigerant management | Decision XXXVI/2, paragraph 1– Include updated relevant information on life-cycle refrigerant management in its 2025 and subsequent progress reports, including the 2026 quadrennial assessment report, taking into account discussions at MOP36 | 2026 progress report |
| 21 | 2026 | Periodic assessments | Replenishment study for 2027–2029 | Expected decision at the 37th MOP, in 2025, and potential additional guidance by OEWG (48th meeting) in 2026 – Prepare a report on the appropriate level of the 2027–2029 replenishment of the Multilateral Fund | Replenishment task force report (2027–2029) | |
| 22 | 2026 | Periodic assessments | Replenishment study for 2027–2029 | Expected decision at the 37th MOP, in 2025, and potential additional guidance by OEWG (48th meeting) in 2026 – Prepare a report on the appropriate level of the 2027–2029 replenishment of the Multilateral Fund | Supplement to the replenishment task force report | |
| 23 | 2026 | Periodic assessments | XXXV/3 | Quadrennial assessment | Decision XXX/3 - Prepare the TEAP 2026 quadrennial assessment | TEAP and TOCs 2026 quadrennial assessment reports (6) |
| 24 | 2026 | Periodic assessments | XXIX/12 | HFCs not listed in Annex F of the Montreal Protocol | Decision XXIX/12 – Provide in the quadrennial reports of the assessment panels to be presented to the 35th MOP, in 2023, and every four years thereafter, information on the consumption and production of HFCs not listed in Annex F of the Protocol that have global warming potential no less than the lowest global warming potential of the HFCs listed in Annex F | 2026 quadrennial assessment report |
| 25 | 2026 | Periodic assessments | XXX/2 | HCFC availability | Decision XXX/2 – Provide in its quadrennial reports to be presented to the 35th MOP, in 2023, and to the 39th MOP, in 2027, information on the availability of Annex C, group I, substances, including amounts available from recovery, recycling and reclamation, and best available information on country-level and total known stocks, as well as the availability of alternative options for the applications described in Article 2F, paragraphs 6 (a) and 6 (b) | 2026 quadrennial assessment report |
| 26 | 2026 | Periodic assessments | XXXVI/2 | Life-cycle refrigerant management | Decision XXXVI/2, paragraph 1– Include updated relevant information on life-cycle refrigerant management in its 2025 and subsequent progress reports, including the 2026 quadrennial assessment report, taking into account discussions at MOP36 | 2026 quadrennial assessment report |
| 27 | 2026 | Periodic assessments | XXXVI/4 | Additional information on very short-lived substances (VSLS) | Decision XXXVI/4, paragraph 1– TEAP and SAP to include the requested information, in their 2026 assessment report, for consideration by OEWG49. | 2026 quadrennial assessment report |
| 28 | 2026 | Periodic assessments | XXXVI/6 | Developments regarding metered-dose inhalers with low-global-warming-potential propellants | Decision XXXVI/6, paragraph 3 – Provide updated information, in its annual progress report, on low-GWP metered-dose inhaler propellants, and to complement its 2026 quadrennial assessment report with timely information including on their availability, technical feasibility, economic viability, safety and market penetration in parties operating under paragraph 1 of Article 5 of the Montreal Protocol and those not so doing | 2026 quadrennial assessment report |
| 29 | 2026 | Periodic assessments | XXXVI/10 | Report of the TEAP prepared pursuant to decision XXVIII/2, paragraph 5 | Decision XXXVI/10, provide in its 2026 quadrennial assessment report an update by sector and subsector on low- and lower-GWP alternatives to HFCs for use in Article 5, group 2 parties to prepare for the hydrofluorocarbon freeze, including the following: (a) Challenges and barriers in terms of availability, accessibility and adoption; (b) Standards for alternative refrigerants and for equipment, taking into consideration the capacity of equipment in different countries; (c) Market structure, including supply chain issues; (d) Options for addressing the challenges and barriers to the adoption of alternatives identified in subparagraph (a) above; (e) Information on the cost of adoption of alternatives, in the context of the information provided under subparagraphs (a) to (d) above. | 2026 quadrennial assessment report |
| 30 | 2027 | Progress updates | IV/13 | Technical progress update by TEAP and its TOCs | Decision IV/13 – Report annually to OEWG on technical progress in reducing the use and emissions of controlled substances and assess the use of alternatives, particularly their direct and indirect global-warming effects | 2027 progress report |
| 31 | 2027 | Progress updates | XI/17 | Technical progress update by TEAP and its TOCs | Decision XI/17 – Report on any important new developments on an annual basis | 2027 progress report |
| 32 | 2027 | Progress updates | XXXI/8 | Procedures relevant to nominations to the TEAP and its TOCs. | Decision XXXI/8 – Provide, as part of its annual progress report, a summary outlining the procedures that the Panel and its technical options committees have undertaken to ensure adherence to the Panel’s terms of reference through clear and transparent procedures, including full consultations with the focal points, in line with the terms of reference, regarding: (a) nomination processes, taking into account the matrix of needed expertise and already available expertise; (b) proposed nominations and appointment decisions; (c) termination of appointments; and (d) replacements | 2027 progress report |
| 33 | 2027 | Thematic reports | IX/6 | Critical-use nominations | Decision IX/6 – Review nominations for critical-use exemption of methyl bromide and make recommendations based on the criteria established in the decision (and other relevant decisions) | 2027 progress report (only upon submission of nominations) |
| 34 | 2027 | Thematic reports | IV/25 | Essential-use nominations | Decision IV/25 – Review any submitted nominations and make recommendations in accordance with the criteria established in the decision | 2027 progress report (only upon submission of nominations) |
| 35 | 2027 | Thematic reports | XXXI/5 | Laboratory and analytical uses | Decision XXXI/5 – Report in the TEAP quadrennial report on any progress made by parties in reducing their production and consumption of ozone depleting substances for laboratory and analytical uses, on any new alternatives to those uses, and on laboratory standards that can be performed without such substances, on the understanding that, should new compelling information become available, including opportunities for significant reductions in production and consumption, that information should be reported in its annual progress report | 2027 progress report (only if new compelling information becomes available) |
| 36 | 2027 | Thematic reports | XXXI/6 | Process agents | Decision XXXI/6 – Report in the TEAP quadrennial reports on any progress made by parties in reducing their use and emissions of controlled substances as process agents and on any new alternatives to such uses, including new production processes and emissions-reduction techniques, on the understanding that should new compelling information become available, that information should be reported in its annual progress report | 2027 progress report (only if new compelling information becomes available) |
| 37 | 2027 | Thematic reports | XXX/15 | Process agents; destruction technologies; laboratory and analytical uses; n-propyl bromide; possible new substances | Review only if the specific conditions set out in decision XXX/15 are met | |
| 38 | 2027 | Thematic reports | XXXVI/2 | Life-cycle refrigerant management | Decision XXXVI/2, paragraph 1– Include updated relevant information on life-cycle refrigerant management in its 2025 and subsequent progress reports, including the 2026 quadrennial assessment report, taking into account discussions at MOP36 | 2027 progress report |
| 39 | 2027 | Periodic assessments | XXXV/3 | Quadrennial assessment | Decision XXXV/3 - Prepare the assessment panels’ synthesis report | 2026 quadrennial assessment synthesis report |
| 40 | 2027 | Periodic assessments | XXVIII/2 | Review related to the Kigali Amendment to the Montreal Protocol | Decision XXVIII/2, paragraph 4 – Conduct periodic reviews of alternatives to HFCs in 2022 and every five years thereafter, and provide technological and economic assessments of the latest available and emerging alternatives to HFCs (second review) | Report on review of alternatives to HFCs |
| 41 | 2028 | Progress updates | IV/13 | Technical progress update by TEAP and its TOCs | Decision IV/13 – Report annually to OEWG on technical progress in reducing the use and emissions of controlled substances and assess the use of alternatives, particularly their direct and indirect global-warming effects | 2028 progress report |
| 42 | 2028 | Progress updates | XI/17 | Technical progress update by TEAP and its TOCs | Decision XI/17 – Report on any important new developments on an annual basis | 2028 progress report |
| 43 | 2028 | Progress updates | XXXI/8 | Procedures relevant to nominations to the TEAP and its TOCs. | Decision XXXI/8 – Provide, as part of its annual progress report, a summary outlining the procedures that the Panel and its technical options committees have undertaken to ensure adherence to the Panel’s terms of reference through clear and transparent procedures, including full consultations with the focal points, in line with the terms of reference, regarding: (a) nomination processes, taking into account the matrix of needed expertise and already available expertise; (b) proposed nominations and appointment decisions; (c) termination of appointments; and (d) replacements | 2028 progress report |
| 44 | 2028 | Thematic reports | IX/6 | Critical-use nominations | Decision IX/6 – Review nominations for critical-use exemption of methyl bromide and make recommendations based on the criteria established in the decision (and other relevant decisions) | 2028 progress report (only upon submission of nominations) |
| 45 | 2028 | Thematic reports | IV/25 | Essential-use nominations | Decision IV/25 – Review any submitted nominations and make recommendations in accordance with the criteria established in the decision | 2028 progress report (only upon submission of nominations) |
| 46 | 2028 | Thematic reports | XXXI/5 | Laboratory and analytical uses | Decision XXXI/5 – Report in the TEAP quadrennial report on any progress made by parties in reducing their production and consumption of ozone depleting substances for laboratory and analytical uses, on any new alternatives to those uses, and on laboratory standards that can be performed without such substances, on the understanding that, should new compelling information become available, including opportunities for significant reductions in production and consumption, that information should be reported in its annual progress report | 2028 progress report (only if new compelling information becomes available) |
| 47 | 2028 | Thematic reports | XXXI/6 | Process agents | Decision XXXI/6 – Report in the TEAP quadrennial reports on any progress made by parties in reducing their use and emissions of controlled substances as process agents and on any new alternatives to such uses, including new production processes and emissions-reduction techniques, on the understanding that should new compelling information become available, that information should be reported in its annual progress report | 2028 progress report (only if new compelling information becomes available) |
| 48 | 2028 | Thematic reports | XXX/15 | Process agents; destruction technologies; laboratory and analytical uses; n-propyl bromide; possible new substances | Review only if the specific conditions set out in decision XXX/15 are met | |
| 49 | 2028 | Thematic reports | XXXVI/2 | Life-cycle refrigerant management | Decision XXXVI/2, paragraph 1– Include updated relevant information on life-cycle refrigerant management in its 2025 and subsequent progress reports, including the 2026 quadrennial assessment report, taking into account discussions at MOP36 | 2028 progress report |
| 50 | 2028 | Periodic assessments | XXVIII/2 | Review related to the Kigali Amendment to the Montreal Protocol | Decision XXVIII/2, paragraphs 32 and 33 – Periodically assess the suitability of HFC alternatives for use at high ambient temperatures, starting four years from the HFC freeze date and every four years thereafter (first review) | Assessment of high-ambient-temperature HFC alternatives |
| 51 | 2029 | Progress updates | IV/13 | Technical progress update by TEAP and its TOCs | Decision IV/13 – Report annually to OEWG on technical progress in reducing the use and emissions of controlled substances and assess the use of alternatives, particularly their direct and indirect global-warming effects | 2029 progress report |
| 52 | 2029 | Progress updates | XI/17 | Technical progress update by TEAP and its TOCs | Decision XI/17 – Report on any important new developments on an annual basis | 2029 progress report |
| 53 | 2029 | Progress updates | XXXI/8 | Procedures relevant to nominations to the TEAP and its TOCs. | Decision XXXI/8 – Provide, as part of its annual progress report, a summary outlining the procedures that the Panel and its technical options committees have undertaken to ensure adherence to the Panel’s terms of reference through clear and transparent procedures, including full consultations with the focal points, in line with the terms of reference, regarding: (a) nomination processes, taking into account the matrix of needed expertise and already available expertise; (b) proposed nominations and appointment decisions; (c) termination of appointments; and (d) replacements | 2029 progress report |
| 54 | 2029 | Thematic reports | IX/6 | Critical-use nominations | Decision IX/6 – Review nominations for critical-use exemption of methyl bromide and make recommendations based on the criteria established in the decision (and other relevant decisions) | 2029 progress report (only upon submission of nominations) |
| 55 | 2029 | Thematic reports | IV/25 | Essential-use nominations | Decision IV/25 – Review any submitted nominations and make recommendations in accordance with the criteria established in the decision | 2029 progress report (only upon submission of nominations) |
| 56 | 2029 | Thematic reports | XXXI/5 | Laboratory and analytical uses | Decision XXXI/5 – Report in the TEAP quadrennial report on any progress made by parties in reducing their production and consumption of ozone depleting substances for laboratory and analytical uses, on any new alternatives to those uses, and on laboratory standards that can be performed without such substances, on the understanding that, should new compelling information become available, including opportunities for significant reductions in production and consumption, that information should be reported in its annual progress report | 2029 progress report (only if new compelling information becomes available) |
| 57 | 2029 | Thematic reports | XXXI/6 | Process agents | Decision XXXI/6 – Report in the TEAP quadrennial reports on any progress made by parties in reducing their use and emissions of controlled substances as process agents and on any new alternatives to such uses, including new production processes and emissions-reduction techniques, on the understanding that should new compelling information become available, that information should be reported in its annual progress report | 2029 progress report (only if new compelling information becomes available) |
| 58 | 2029 | Thematic reports | XXX/15 | Process agents; destruction technologies; laboratory and analytical uses; n-propyl bromide; possible new substances | Review only if the specific conditions set out in decision XXX/15 are met | |
| 59 | 2029 | Thematic reports | XXXVI/2 | Life-cycle refrigerant management | Decision XXXVI/2, paragraph 1– Include updated relevant information on life-cycle refrigerant management in its 2025 and subsequent progress reports, including the 2026 quadrennial assessment report, taking into account discussions at MOP36 | 2029 progress report |
| 60 | 2029 | Periodic assessments | Replenishment study for 2030–2032 | Expected decision at the 40th MOP, in 2028, and potential additional guidance by OEWG (51st meeting) in 2029 – Prepare a report on the appropriate level of the 2030–2032 replenishment of the Multilateral Fund | Replenishment task force report (2030–2032) | |
| 61 | 2029 | Periodic assessments | Replenishment study for 2030–2032 | Expected decision at the 40th MOP, in 2028, and potential additional guidance by OEWG (51st meeting) in 2029 – Prepare a report on the appropriate level of the 2030–2032 replenishment of the Multilateral Fund | Supplement to the replenishment task force report | |
| 62 | 2030 | Progress updates | IV/13 | Technical progress update by TEAP and its TOCs | Decision IV/13 – Report annually to OEWG on technical progress in reducing the use and emissions of controlled substances and assess the use of alternatives, particularly their direct and indirect global-warming effects | 2030 progress report |
| 63 | 2030 | Progress updates | XI/17 | Technical progress update by TEAP and its TOCs | Decision XI/17 – Report on any important new developments on an annual basis | 2030 progress report |
| 64 | 2030 | Progress updates | XXXI/8 | Procedures relevant to nominations to the TEAP and its TOCs. | Decision XXXI/8 – Provide, as part of its annual progress report, a summary outlining the procedures that the Panel and its technical options committees have undertaken to ensure adherence to the Panel’s terms of reference through clear and transparent procedures, including full consultations with the focal points, in line with the terms of reference, regarding: (a) nomination processes, taking into account the matrix of needed expertise and already available expertise; (b) proposed nominations and appointment decisions; (c) termination of appointments; and (d) replacements | 2030 progress report |
| 65 | 2030 | Thematic reports | IX/6 | Critical-use nominations | Decision IX/6 – Review nominations for critical-use exemption of methyl bromide and make recommendations based on the criteria established in the decision (and other relevant decisions) | 2030 progress report (only upon submission of nominations) |
| 66 | 2030 | Thematic reports | IV/25 | Essential-use nominations | Decision IV/25 – Review any submitted nominations and make recommendations in accordance with the criteria established in the decision | 2030 progress report (only upon submission of nominations) |
| 67 | 2030 | Thematic reports | XXXI/5 | Laboratory and analytical uses | Decision XXXI/5 – Report in the TEAP quadrennial report on any progress made by parties in reducing their production and consumption of ozone depleting substances for laboratory and analytical uses, on any new alternatives to those uses, and on laboratory standards that can be performed without such substances, on the understanding that, should new compelling information become available, including opportunities for significant reductions in production and consumption, that information should be reported in its annual progress report | 2030 quadrennial assessment report |
| 68 | 2030 | Thematic reports | XXXI/6 | Process agents | Decision XXXI/6 – Report in the TEAP quadrennial reports on any progress made by parties in reducing their use and emissions of controlled substances as process agents and on any new alternatives to such uses, including new production processes and emissions-reduction techniques, on the understanding that should new compelling information become available, that information should be reported in its annual progress report | 2030 quadrennial assessment report |
| 69 | 2030 | Thematic reports | XXX/15 | Process agents; destruction technologies; laboratory and analytical uses; n-propyl bromide; possible new substances | Review only if the specific conditions set out in decision XXX/15 are met | |
| 70 | 2030 | Thematic reports | XXXVI/2 | Life-cycle refrigerant management | Decision XXXVI/2, paragraph 1– Include updated relevant information on life-cycle refrigerant management in its 2025 and subsequent progress reports, including the 2026 quadrennial assessment report, taking into account discussions at MOP36 | 2030 progress report |
| 71 | 2030 | Periodic assessments | Quadrennial assessment | Expected decision at the 39th MOP, in 2027 - Prepare the TEAP 2030 quadrennial assessment | TEAP and TOCs 2030 quadrennial assessment reports (6) | |
| 72 | 2030 | Periodic assessments | XXIX/12 | HFCs not listed in Annex F of the Montreal Protocol | Decision XXIX/12 – Provide in the quadrennial reports of the assessment panels to be presented to the 35th MOP, in 2023, and every four years thereafter, information on the consumption and production of HFCs not listed in Annex F of the Protocol that have global warming potential no less than the lowest global warming potential of the HFCs listed in Annex F | 2030 quadrennial assessment reports |
1 The provisions of decision XXX/15 regarding process agents and laboratory and analytical uses are superceded by decisions XXXI/6 and XXXI/5, respectively. The process of dealing with possible new substances is set out in decision IX/24.
2 Reports to be produced on the listed issues are not indicated herein given that the time at which the respective conditions set out in decision XXX/15 will be met is not known.